CLEC2A antibody-saporin conjugate

The CLEC2A antibody-saporin conjugate is an experimental antibody-drug conjugate (ADC) targeting C-type lectin domain family 2 member A (CLEC2A), a surface antigen highly expressed in high-risk acute myeloid leukemia (AML), particularly those with KMT2A rearrangements. The drug consists of a monoclonal antibody specific for CLEC2A conjugated to saporin, a type II ribosome-inactivating protein (RIP) derived from the plant Saponaria officinalis. Upon binding to the target cell surface and subsequent internalization, the saporin payload is released into the cytosol where it depurinates the sarcin/ricin loop of the 28S ribosomal RNA, irreversibly halting protein synthesis and inducing apoptosis. Developed by researchers at the Fred Hutchinson Cancer Center and Seattle Children's Hospital, this ADC is designed to provide a targeted treatment option for AML subtypes that are often refractory to conventional chemotherapy, while minimizing off-target toxicity due to the absence of CLEC2A expression in normal hematopoietic tissues.

Other names

anti-CLEC2A-saporin conjugateanti-CLEC-2A-saporin conjugateanti-CLEC 2A-saporin conjugateCLEC2A-ADCCLEC-2A-ADCCLEC 2A-ADC